Related Experiment Video
Updated: Jun 13, 2026
09:24
Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
Published on: June 9, 2016
Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview
Zinnia P Parra-Guillén1, Gloria González-Aseguinolaza, Pedro Berraondo
1Department of Pharmacy and Pharmaceutical Technology School of Pharmacy, University of Navarra, Pamplona, Spain.
Pharmaceutical Research
|April 14, 2010
Summary
Quantitative modeling of nonviral vectors in gene therapy is crucial for improving their low in vivo efficiency. This review analyzes studies on DNA time-course to guide vector optimization for enhanced gene delivery.
Area of Science:
- Biomedical Engineering
- Molecular Biology
- Pharmacology
Background:
- Gene therapy has over 20 years of clinical trials, with nonviral vectors showing promise but limited in vivo efficiency.
- Understanding intracellular behavior of nonviral vectors is key to enhancing their performance.
- Model-based approaches offer powerful tools for analyzing gene transfer systems.
Purpose of the Study:
- To critically review quantitative studies and models of naked or formulated DNA time-course.
- To elucidate intracellular vector behavior for improved nonviral vector design.
- To highlight the utility of model-based approaches in gene therapy optimization.
Main Methods:
- Literature review of quantitative studies on DNA pharmacokinetics.
- Analysis of modeling approaches for nonviral vector gene transfer.
- Synthesis of data on intracellular DNA fate and transport.
Main Results:
- Identified a need for further improvements in nonviral vector efficiency.
- Highlighted the value of quantitative modeling in understanding vector performance.
- Demonstrated the potential of model-based approaches to predict outcomes.
Conclusions:
- Quantitative analysis and modeling are essential for advancing nonviral vector gene therapy.
- Further research into intracellular dynamics can optimize vector design.
- Model-based strategies can accelerate the development of effective gene therapies.
More Related Videos
Related Concept Videos
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:20Pharmacokinetic Models: Overview
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...